Wensink G Emerens, Elias Sjoerd G, Mullenders Jasper, Koopman Miriam, Boj Sylvia F, Kranenburg Onno W, Roodhart Jeanine M L
Department of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.
Department of Epidemiology, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.
NPJ Precis Oncol. 2021 Apr 12;5(1):30. doi: 10.1038/s41698-021-00168-1.
Effective predictive biomarkers are needed to enable personalized medicine and increase treatment efficacy and survival for cancer patients, thereby reducing toxic side effects and treatment costs. Patient-derived organoids (PDOs) enable individualized tumour response testing. Since 2018, 17 publications have examined PDOs as a potential predictive biomarker in the treatment of cancer patients. We review and provide a pooled analysis of the results regarding the use of PDOs in individualized tumour response testing, focusing on evidence for analytical validity, clinical validity and clinical utility. We identify future perspectives to accelerate the implementation of PDOs as a predictive biomarker in the treatment of cancer patients.
需要有效的预测性生物标志物来实现个性化医疗，并提高癌症患者的治疗效果和生存率，从而减少毒副作用和治疗成本。患者来源的类器官（PDO）可用于个体化肿瘤反应测试。自2018年以来，已有17篇出版物研究了PDO作为癌症患者治疗中潜在预测性生物标志物的情况。我们回顾并对关于PDO在个体化肿瘤反应测试中的应用结果进行汇总分析，重点关注分析有效性、临床有效性和临床实用性的证据。我们确定了加速将PDO作为预测性生物标志物应用于癌症患者治疗的未来前景。
